Showing items related by title and author.

• Temporary Authorization for Use: Does the French Patient Access Programme for Unlicensed Medicines Impact Market Access After Formal Licensing? 

  Degrassat-Théas, Albane; Paubel, Pascal; Parent de Curzon, Olivier; Le Pen, Claude; Sinègre, Martine (2013) Article accepté pour publication ou publié
• Is Orphan Designation a Driver of Orphan Drug Pricing? 

  Degrassat-Théas, Albane; Le Pen, Claude; Parent de Curzon, Olivier; Paubel, Pascal; Poisson, N.; Sinègre, Martine (2012) Article accepté pour publication ou publié
• Public regulation of the cancer drugs market in French hospitals 

  Le Pen, Claude; Rieu, C.; Bensadon, M.; Degrassat-Théas, Albane; Paubel, Pascal (2009-10) Communication / Conférence
• Hospital Reimbursement Price Cap for Cancer Drugs: the French experience in controlling hospital drug expenditures 

  Degrassat-Théas, Albane; Bensadon, M.; Rieu, C.; Angalakuditi, M.; Le Pen, Claude; Paubel, Pascal (2012) Article accepté pour publication ou publié
• A Long War Begins: Biosimilars Versus Patented Biologics – A Retrospective Analysis Of The Eu-5 And Japanese Erythropoetins Markets 

  Bocquet, François; Paubel, Pascal; Fusier, Isabelle; Cordonnier, Anne-Laure; Le Pen, Claude; Sinègre, Martine (2014) Article accepté pour publication ou publié